small-logo
ProfessionalsCapabilitiesInsights & NewsCareersLocations
About UsAlumniOpportunity & InclusionPro BonoCorporate Social Responsibility
Stay Connected:
facebookinstagramlinkedintwitteryoutube

Class Action Insider

    • Email
    • LinkedIn
    • Facebook
    • Twitter
    Share this page
  • RSSRSS
Topics
Contributors
Start Date
End Date

Sort by:

2 results

July 3, 2024

|

3 min read

Microplastics Are the Latest Trend in “Greenwashing” Litigation

Recent lawsuits claim baby bottle manufacturers deceived consumers by representing sippy cups and baby bottles were “BPA free” and therefore safe for use despite, plaintiffs allege, that heating these products could cause microplastics to leak into food and drinks.

...Read more

September 20, 2023

|

4 min read

MoCRA Makes Way for Primary-Jurisdiction Defense in PFAS Litigation in the Cosmetic Industry

On December 29, 2022, President Biden signed the Modernization of Cosmetics Regulation Act (MoCRA) into law. One provision of MoCRA charges the FDA to conduct research into the use of perfluoroalkyl and polyfluoroalkyl substances—better known as PFAS—in the cosmetic industry, and to publish a report containing its findings by December 29, 2025.

...Read more

About This Blog

Winston & Strawn’s Class Action Insider is a biweekly series that provides recent developments and emerging trends in class action law. 

Contributors

Jeffrey J. Amato

Partner

Ronald Y. Rothstein

Partner

Sean G. Wieber

Partner

Jeff Wilkerson

Partner

Shawn R. Obi

Partner

Related Capabilities

  • Technology, Media & Telecommunications
  • Financial Services
  • Healthcare

Webinar

Listen Here

Get Our Updates

Subscribe

Related Insights & News

Blog
FDA Issues Guidance to Clarify Recommendations Regarding Timely Initiation of Voluntary Recalls

March 10, 2022

Client Alert
FDA Publishes Guidance on the Enhanced System Under the DSCSA Going into Effect on November 27, 2023

July 14, 2021

Client Alert
FDA Publishes Guidance on the Identification and Notification of Suspect Products as Part of the Implementation of the Drug Supply Chain Security Act

June 23, 2021

Client Alert
FDA Conforms Regulations to Exclude Certain Software Functions from the Definition of Device

May 20, 2021

Client Alert
FDA Develops Guidance for Enhancing the Diversity of Clinical Trial Populations

November 17, 2020

Client Alert
FDA Identifies Essential Medicines, Medical Countermeasures, and Critical Inputs Required by Executive Order 13944

November 6, 2020

Client Alert
FDA Provides Guidance to Manufacturers for Controlling Nitrosamine Impurities in Human Drugs

September 18, 2020

Client Alert
New FDA Guidance Issued to Help Drug and Biologics Manufacturers Resume Normal Manufacturing Operations

September 15, 2020

Client Alert
FDA Calls for Comments on Its Extensive Draft Guidance on Use of Patient-Reported Outcome Instruments in Medical Device Lifecycle Analysis

September 4, 2020

Client Alert
FDA Issues New Guidance for Reporting on Shortages of Drugs and Biologics

April 2, 2020

Client Alert
FDA Relaxes Certain Lab and Imaging Test Requirements for REMS Programs During the COVID-19 Pandemic

March 27, 2020

In the Media
Nimalka Wickramasekera Examines the FDA’s AI Regulatory Framework

April 10, 2019

Blog
FDA Issues Guidance to Clarify Recommendations Regarding Timely Initiation of Voluntary Recalls
March 10, 2022
Client Alert
FDA Publishes Guidance on the Enhanced System Under the DSCSA Going into Effect on November 27, 2023
July 14, 2021
Client Alert
FDA Publishes Guidance on the Identification and Notification of Suspect Products as Part of the Implementation of the Drug Supply Chain Security Act
June 23, 2021
Client Alert
FDA Conforms Regulations to Exclude Certain Software Functions from the Definition of Device
May 20, 2021
Client Alert
FDA Develops Guidance for Enhancing the Diversity of Clinical Trial Populations
November 17, 2020
Client Alert
FDA Identifies Essential Medicines, Medical Countermeasures, and Critical Inputs Required by Executive Order 13944
November 6, 2020
Client Alert
FDA Provides Guidance to Manufacturers for Controlling Nitrosamine Impurities in Human Drugs
September 18, 2020
Client Alert
New FDA Guidance Issued to Help Drug and Biologics Manufacturers Resume Normal Manufacturing Operations
September 15, 2020
Client Alert
FDA Calls for Comments on Its Extensive Draft Guidance on Use of Patient-Reported Outcome Instruments in Medical Device Lifecycle Analysis
September 4, 2020
Client Alert
FDA Issues New Guidance for Reporting on Shortages of Drugs and Biologics
April 2, 2020
Client Alert
FDA Relaxes Certain Lab and Imaging Test Requirements for REMS Programs During the COVID-19 Pandemic
March 27, 2020
In the Media
Nimalka Wickramasekera Examines the FDA’s AI Regulatory Framework
April 10, 2019
Logo
facebookinstagramlinkedintwitteryoutube

Copyright © 2025. Winston & Strawn LLP

AlumniCorporate Transparency Act Task ForceDEI Compliance Task ForceEqual Rights AmendmentLaw GlossaryThe Oval UpdateWinston MinutePrivacy PolicyCookie PolicyFraud & Scam AlertsNoticesSubscribeAttorney Advertising